Comparable stake leader
OPKO HEALTH, INC.
SEC ownership of Cocrystal Pharma, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001412486.
Disclosed value leader
OPKO HEALTH, INC.
Comparable rows
2/35
Latest evidence
05 Aug 2026
- Public ticker
- COCP on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
OPKO HEALTH, INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 35
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
OPKO HEALTH, INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
05 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001412486
- Issuer location
- Bothell, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Cocrystal Pharma, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
OPKO HEALTH, INC.
Disclosed value leader
OPKO HEALTH, INC.
Comparable rows
2/35
Latest evidence
05 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 30%
33 rows are not safely comparable across share classes.
13D/G row: OPKO HEALTH, INC.
Showing 1-8 of 35 holder rows.
Quick read
OPKO HEALTH, INC. leads the comparable SEC ownership view at 30%.
2 of 35 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens OPKO HEALTH, INC.'s linked filing trail.
Comparable ownership
Top 2
OPKO HEALTH, INC.
30%
Frost Phillip MD Et al
14%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 35 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| OPKO HEALTH, INC. |
13D/G
|
30%
Reported 13D/G
· 31 Jul 2026
|
$5,977,562
5,692,916 shares
|
$0 | 31 Jul 2026 |
| Frost Phillip MD Et al |
3/4/5
13D/G
Director, 10%+ Owner · Phillip Frost, M.D.
|
14%
Reported 13D/G
· 03 Aug 2026
|
$2,985,326
2,764,692 shares
mixed-class rows
|
+$300,212 | 05 Aug 2026 |
| Fred Hassan |
3/4/5
Director
|
—
mixed-class rows
|
$2,922,384
2,118,845 shares
mixed-class rows
|
— | 09 Jan 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$376,139
358,228 shares
|
— | 30 Jun 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$188,609
179,628 shares
|
— | 30 Jun 2026 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
—
denominator unverified
|
$184,148
175,379 shares
|
— | 30 Jun 2026 |
| Richard C. Pfenniger Jr. |
3/4/5
Director
|
—
mixed-class rows
|
$94,867
87,810 shares
mixed-class rows
|
— | 09 Jan 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$80,034
76,208 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$300,212.
Buys
$300,212
Insiders: 1
Sells
$0
Insiders: 0
Net
+$300,212
Shares: +314,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 314,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 10,000 | 0 | $9,816 | $0 | +$9,816 |
| 3-6 | 75,000 | 0 | $70,590 | $0 | +$70,590 |
| 6-9 | 70,000 | 0 | $67,232 | $0 | +$67,232 |
| 9-12 | 159,000 | 0 | $152,574 | $0 | +$152,574 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Cocrystal Pharma, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Frost Phillip MD Et al
Net 12M change
+$300.21K
Full value: +$300,212 · USD · 12-month changeLatest report
12 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Frost Phillip MD Et al | Director, 10%+ Owner | $2,985,326 | +$300,212 | +11% | Mixed | 05 Aug 2026 |
| Fred Hassan | Director | $2,922,384 | Mixed | 09 Jan 2026 | ||
| Richard C. Pfenniger Jr. | Director | $94,867 | Mixed | 09 Jan 2026 | ||
| James Joseph Martin | Co-CEO and CFO | $71,394 | Mixed | 09 Jan 2026 | ||
| James Sapirstein | Chief Executive Officer | Mixed | 03 Jun 2026 | |||
| Sam Lee | President and Co-CEO | Mixed | 09 Jan 2026 | |||
| Carol L. Brosgart | Director | Mixed | 12 Aug 2026 | |||
| Anthony J. Japour | Director | Mixed | 09 Jan 2026 | |||
| Roger D. Kornberg | Director | Mixed | 09 Jan 2026 | |||
| Steven D. Rubin | Director | Mixed | 09 Jan 2026 |
Recent insider transactions for Cocrystal Pharma, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 0.5% | $9,816 | $0.9816 | 10,000 | 1,993,551 | 05 Aug 2026 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 3.93% | $70,590 | $0.9412 | 75,000 | 1,983,551 | 03 Aug 2026 | By Frost Gamma Investments Trust |
| James Sapirstein | COCP | Stock Options (Right to Buy) | Award | 235,000 | 235,000 | 03 Jun 2026 | Direct | |||
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.06% | $19,952 | $0.9976 | 20,000 | 1,908,551 | 24 Feb 2026 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 2.72% | $47,280 | $0.9456 | 50,000 | 1,888,551 | 06 Feb 2026 | By Frost Gamma Investments Trust |
| Roger D. Kornberg | COCP | Stock Options (Right to Buy) | Award | 24,615 | 24,615 | 09 Jan 2026 | Direct | |||
| Richard C. Pfenniger Jr. | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| Sam Lee | COCP | Stock Options (Right to Buy) | Award | 49,229 | 49,229 | 09 Jan 2026 | Direct | |||
| Fred Hassan | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| James Joseph Martin | COCP | Stock Options (Right to Buy) | Award | 49,229 | 49,229 | 09 Jan 2026 | Direct | |||
| Et al Phillip Frost MD | COCP | Stock Options (Right to Buy) | Award | 24,615 | 24,615 | 09 Jan 2026 | Direct | |||
| Anthony J. Japour | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| Steven D. Rubin | COCP | Stock Options (Right to Buy) | Award | 16,410 | 16,410 | 09 Jan 2026 | Direct | |||
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 2.8% | $47,275 | $0.9455 | 50,000 | 1,838,551 | 31 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.13% | $19,310 | $0.9655 | 20,000 | 1,788,551 | 30 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 2.31% | $38,944 | $0.9736 | 40,000 | 1,768,551 | 26 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.47% | $24,258 | $0.9703 | 25,000 | 1,728,551 | 24 Dec 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 0.24% | $3,975 | $0.9938 | 4,000 | 1,703,551 | 26 Nov 2025 | By Frost Gamma Investments Trust |
| Et al Phillip Frost MD | COCP | Common Stock | Purchase | 1.19% | $18,812 | $0.9406 | 20,000 | 1,699,551 | 25 Nov 2025 | By Frost Gamma Investments Trust |
* marks a reported price that did not pass the local price check.